| P/E (FY) | — | Sales (TTM) | $16,565 |
| Earnings (TTM) | -$6.7M | ROE | −78.62% |
| Net Margin | −43832.49% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 149.89% |
| Market Cap | $4.6M | Trading Days | 937 |
| 52W High | 7.91 |
| 52W Low | 0.97 |
| % Off High | −80.28% |
| YTD | −42.44% | 1Y | −62.95% |
| 3Y | −95.40% | Since incept. (ann.) | −68.17% |
Reportable Segments 100%
| Ann. Volatility (1Y) | 149.04% | Ann. Volatility (3Y) | 184.65% |
| Sharpe (1Y) | −0.03 | Sharpe (3Y) | 0.21 |
| Max Drawdown (1Y) | −79.08% | Max Drawdown (3Y) | −98.86% |
| Beta (3Y, vs SPY) | 7.15 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| BMRA | BIOMERICA INC | $4.9M | — |
| QCLS | Q/C TECHNOLOGIES, INC. | $25.3M | — |
| ICCC | IMMUCELL CORP /DE/ | $101.7M | — |
| IMDX | Insight Molecular Diagnostics Inc. | $148.9M | — |
| TKNO | Alpha Teknova, Inc. | $260.0M | — |
| MYGN | MYRIAD GENETICS INC | $502.5M | — |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $634.4M | — |
| QDEL | QuidelOrtho Corp | $1.14B | — |
| NTLA | Intellia Therapeutics, Inc. | $1.52B | — |
| NEOG | NEOGEN CORP | $2.00B | — |
| CLDX | Celldex Therapeutics, Inc. | $2.79B |
| — |
| LNTH | Lantheus Holdings, Inc. | $6.68B | 30.1 |
